Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03915184 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
A Phase 1 study of Multiple Myeloma, sponsored by CARsgen Therapeutics Co..
- Active
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 13
- Study locations
NCT03915184 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by CARsgen Therapeutics Co.. The registered enrollment target is 105 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT03915184, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by CARsgen Therapeutics Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 13
- Study locations
Study Summary
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
Conditions Studied
Interventions
- BIOLOGICAL zevor-cel
Study Locations (13)
Texas
- UT Southwestern Medical Center - Dallas
- MD Anderson - Houston
- Methodist Hosptial - Houston
Arizona
- Mayo Clinic Hospital - Phoenix
California
- UCSF - San Francisco
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Dana Farber Cancer Center - Boston
Minnesota
- Mayo - Rochester
Tennessee
- TriStar CMC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2034-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03915184
The ClinicalTrials.gov registry entry for NCT03915184 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The listed sponsor is CARsgen Therapeutics Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which zevor-cel is the first listed.
NCT03915184 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Texas, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03915184 about?
NCT03915184 is a clinical study titled "Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)". A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
What is the current status of trial NCT03915184?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2019-09-25. Estimated completion is 2034-12-31.
What conditions does trial NCT03915184 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03915184?
The interventions under investigation include: zevor-cel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03915184?
This trial is sponsored by CARsgen Therapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03915184 being conducted?
This trial has 13 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.